These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22005475)

  • 21. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab.
    Tanvetyanon T; Murtagh R; Bepler G
    J Thorac Oncol; 2009 Feb; 4(2):268-9. PubMed ID: 19179909
    [No Abstract]   [Full Text] [Related]  

  • 22. Bevacizumab in lung cancer: hurdles in clinical development.
    Pirker R
    Lancet Oncol; 2010 Aug; 11(8):703-4. PubMed ID: 20650687
    [No Abstract]   [Full Text] [Related]  

  • 23. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit.
    Dişel U; Beşen AA; Özyılkan Ö; Er E; Canpolat T
    Oral Oncol; 2012 Feb; 48(2):e2-3. PubMed ID: 21865077
    [No Abstract]   [Full Text] [Related]  

  • 24. How should we use bevacizumab in patients with non-small cell lung cancer?
    Kim YH; Mishima M
    J Thorac Oncol; 2011 Dec; 6(12):2145-6. PubMed ID: 22088996
    [No Abstract]   [Full Text] [Related]  

  • 25. Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis.
    Tabouret T; Gregory T; Dhooge M; Brezault C; Mir O; Dréanic J; Chaussade S; Coriat R
    Invest New Drugs; 2015 Oct; 33(5):1144-7. PubMed ID: 26311072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diaphragmatic rupture, a new complication of Bevacizumab.
    Lacaze L; Scotté M
    Eur J Surg Oncol; 2012 Nov; 38(11):1079-81. PubMed ID: 22818843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.
    Dansin E; Cinieri S; Garrido P; Griesinger F; Isla D; Koehler M; Kohlhaeufl M
    Lung Cancer; 2012 Jun; 76(3):373-9. PubMed ID: 22236866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event.
    Thakker M; Quadri K; Desai A; Illyas W; Kim MY; Desai S; Rager C
    J Oncol Pract; 2019 Nov; 15(11):613-614. PubMed ID: 31580769
    [No Abstract]   [Full Text] [Related]  

  • 30. Prognosis of metastatic carcinoma of the lung in the bevacizumab era: comparison between the major histologic types of lung cancer.
    Wachtel MS; Jumper CA; Halldorsson AO
    J Surg Res; 2012 May; 174(1):20-3. PubMed ID: 21872272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
    Cancer Discov; 2014 Nov; 4(11):OF18. PubMed ID: 25367959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Cao C; Wang J; Bunjhoo H; Xu Y; Fang H
    Acta Oncol; 2012 Feb; 51(2):151-6. PubMed ID: 22085338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
    Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B
    Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of bevacizumab treatments and metastatic sites of lung cancer.
    Sato H; Nagashima H; Akiyama M; Ito T; Hashimoto T; Saikawa H; Utsumi Y; Maemondo M
    Cancer Treat Res Commun; 2021; 26():100290. PubMed ID: 33373900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results.
    Zustovich F; Ferro A; Lombardi G; Farina P; Zagonel V
    Chemotherapy; 2014; 60(5-6):294-9. PubMed ID: 25999127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and tolerance of bevacizumab in non-small cell lung cancer: preliminary report].
    Mazières J; Dansin E
    Rev Pneumol Clin; 2008 Aug; 64(4):166-72. PubMed ID: 19019283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
    Socinski MA; Langer CJ; Huang JE; Kolb MM; Compton P; Wang L; Akerley W
    J Clin Oncol; 2009 Nov; 27(31):5255-61. PubMed ID: 19738122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
    Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
    Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology.
    Morgensztern D; Govindan R
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S57-61. PubMed ID: 21885000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.